Beta Bionics (BBNX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.38
- Estimate
- -$0.51
- Surprise
- +26.6%
- Revenue (period 2026-09-30)
- $35.5M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Beta Bionics (BBNX) reported a narrower loss than forecast — adjusted EPS of -$0.38 against the -$0.51 estimate (a 26.6% beat on a still-unprofitable quarter).
Coverage in the report window
- Beta Bionics Q3 2026 Earnings Call Transcript — benzinga, 2026-10-27
- 12 Health Care Stocks Moving In Tuesday's After-Market Session — benzinga, 2026-10-27
- Beta Bionics Raises FY2026 Sales Guidance from $121.000M-$126.000M to $124.000M-$126.000M vs $126.626M Est — benzinga, 2026-10-27
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBNX Sell at 5.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +26.6% surprise compares with a +33.0% four-quarter average.
What argues against it
- Concentration risk — Product: iLet
- Concentration risk — Customer: top four DME distributors (52.0%)
- Target reached (-1.4% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.39
- Stop
- $19.89
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
BBNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.15B
- P/E (fwd)
- -9.9
- 52-week range
- $8.80–$32.71
- Off 52-week high
- 34.6%
- RSI (14)
- 69
- Volume vs avg
- 1.38×
- Score today
- 5.6/10